In the lab and in the clinic, alisertib with TAK-228 excels against solid tumors

November 1, 2017, CU Anschutz Medical Campus
University of Colorado Cancer Center investigator, Jennifer Diamond, MD, and colleagues report promising phase I results of alisertib with TAK-228 against solid tumors including triple-negative breast cancer. Credit: University of Colorado Cancer Center

Two University of Colorado Cancer Center studies were presented this weekend at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting in Philadelphia, PA showing that using the drug alisertib along with the drug TAK-228 is more effective against triple-negative breast cancer and solid tumors than either drug alone. The first study details the scientific work that forms the basis for the second study, which presents results of an ongoing phase 1 dose-escalation clinical trial of this combination in patients with advanced solid tumors.

Previous work implicates a kinase called Aurora A in the development and growth of breast cancer. The drug alisertib inhibits this kinase. This drug has the ability to kill many types of cancer cells; however, rather than dying in response to aurora A kinase inhibition, some cells enter a sleep-like state known as senescence. Senescence may be good - cells stop dividing quickly - but cell death is better.

"Unfortunately, even in this senescent state, triple-negative can signal their neighbors to grow," says Jennifer Diamond, MD, investigator at CU Cancer Center and the study's first author. In fact, work in the Diamond lab and elsewhere shows that when triple-negative breast cancer cells become senescent, the cancer can, in fact, continue to grow.

The Diamond lab has also shown that when triple-negative breast cancer cells are treated with aurora A kinase inhibitors, they increase their signaling through a pathway known as mTOR.

"The first study we presented shows that mTOR is important for these cells to maintain senescence," Diamond says.

When the group used TAK-228 to block mTOR signaling, instead of becoming senescent, triple-negative breast cancer cells died. In other words, it seemed as if these cells were using mTOR to escape alisertib. And using TAK-228 to block mTOR nixed this escape.

To confirm this effect, the group collaborated with James Orth, PhD, assistant research professor at CU Boulder, to apply a fluorescent labeling system to show where cells treated with each drug alone and in combination were in their cycle of replication. Alone, alisertib and TAK-228 each resulted in cell cycle arrest - the cells stopped partway through the cell cycle to become senescent. When the group combined alisertib with TAK-228, instead of cell cycle arrest, cancer entered the cell death known as apoptosis.

"Now we had this rational combination," Diamond says. The group submitted their findings through the investigator-initiated research program of the company Takeda, which manufactures both alisertib and TAK-228. "We were approved," Diamond says. "They would provide the drug and we would run the study."

Led by Diamond and presented by first author, CU Cancer Center investigator, S. Lindsey Davis, MD, the phase 1 clinical trial (NCT02719691) of alisertib with TAK-228 in patients with advanced solid tumors opened in 2016. Results presented this weekend of 16 patients treated in the ongoing trial show that the combination was generally well-tolerated, with the most common side effects being fatigue (19%) and decreased neutrophil count (31%). The maximum tolerated dose was found to be a cycle of 30mg of alisertib each day for a week, followed by two weeks off, combined with 2mg of TAK-228 every day.

"We had multiple patients that were on the trial for a long time - a breast cancer patients who was on treatment for over a year and a prostate patient whose disease continues to be under control for almost a year, both good results for a phase 1 study," Diamond says.

The drug's promise now results in an expansion of the trial to an additional 20 patients, which is meant to further refine appropriate dosing and dose schedules, and to work toward identifying the characteristics of patients most likely to benefit from the combination.

"I think it's promising," Diamond says. "We definitely had who saw clinical benefit from the treatment."

Explore further: Powerful drug combo gangs up to tackle triple-negative breast cancer

Related Stories

Powerful drug combo gangs up to tackle triple-negative breast cancer

September 26, 2017
In the hunt for novel treatments against an aggressive form of breast cancer, researchers combined a new protein inhibitor with a chemotherapy drug to create a powerful combination that resulted in cancer cell death.

Paragazole excels in preclinical models of triple-negative breast cancer

April 8, 2013
Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative breast ...

Trial to test new drug in patients with advanced cancer

August 23, 2017
A clinical trial to test a new cancer drug in patients with advanced solid tumours, launches in four centres across the UK, through Cancer Research UK's Centre for Drug Development.

Promising findings towards targeted breast cancer therapy

November 14, 2016
New research led by Conway Fellow, Professor Joe Duffy and Professor John Crown in St Vincent's University Hospital has reported for the first time on a new treatment that could be used in the majority of patients with triple ...

Discovery of potential treatment for aggressive form of breast cancer

November 2, 2016
A new drug could be used to treat one of the most aggressive forms of breast cancer, a research centre based at University College Dublin and St Vincent's Hospital has discovered.

Even low-androgen triple-negative breast cancer responds to anti-androgen therapy

February 24, 2015
A University of Colorado Cancer Center study published today in the journal Molecular Cancer Therapeutics shows that only about 1 percent of triple-negative breast cancer cells in a tumor must be "androgen-receptor-positive" ...

Recommended for you

Two studies describe improved approach to bone marrow transplant

September 25, 2018
Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that preclinical laboratory tests suggest could make the life-saving procedure safer and more effective for patients.

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

September 25, 2018
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...

Combo therapy of prostatectomy plus radiotherapy may improve survival in prostate cancer

September 25, 2018
High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective ...

A protein called vaccinia-related kinase 1 may help cancer establish itself in new areas of the body during metastasis

September 25, 2018
Sometimes negative results can point researchers in the right direction.

Method identified to reduce risk of brain damage in leukemia survivors

September 25, 2018
Children with acute lymphoblastic leukemia (ALL) are at an extremely high risk of sepsis compared to the general population. In the first-published study of its kind, St. Jude Children's Research Hospital scientists have ...

Unhealthy lifestyle responsible for 45,000 predicted cases of bowel cancer in next decade

September 25, 2018
A UNSW study shows that a large proportion of bowel cancers in Australia are preventable by adopting a healthy lifestyle – particularly for men.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.